oncology
Medicines

The grey zone: cancer patients’ reported experiences for checkpoint inhibitors

The first in-depth look at health-related quality of life (HRQOL) toxicity for people receiving checkpoint inhibitors highlights side effects that would be missed using traditional quality of life measures, investigators say. The study relies on patient reported experiences with immune checkpoint modulator (ICM) treatment and is part of a broader series of investigations undertaken to ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic